ArticleHemaSphere2022
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.
Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 138 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh
Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial
Who cites it
138 citing papers in PubMed, 6 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.JCO oncology practice · 2026Pooled it
- [Guideline for transfusion management in Chinese children with transfusion-dependent thalassemia (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Guideline
- Adrenal Insufficiency in Patients with Beta Thalassemia: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies.Reviews on recent clinical trials · 2024Pooled it
- Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good Practice.Blood transfusion = Trasfusione del sangueGuideline
- Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA).Diabetologia · 2026Trial
- Effectiveness of Genetic Counseling Modalities on Knowledge, Attitudes, and Premarital Screening Intentions for Thalassemia Prevention: A Multi-Site Three-Arm Randomized Controlled Trial.International journal of environmental research and public health · 2026Trial
- A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.Journal of blood medicine · 2026Trial
- The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.Frontiers in endocrinology · 2023Trial
- Multisystem Complications in Non-Transfusion-Dependent β-Thalassemia Intermedia: A Case Highlighting the Need for Early Intervention.Clinical case reports · 2026Article
- Mitochondrial Damage in Hemoglobinopathies: The Role of Cell-Free mtDNA as a Potential Biomarker.Biomedicines · 2026Article
- Experience of Prenatal Diagnosis for β-Thalassemia and Major Hemoglobinopathies in the Last Decade from Seven Tertiary-Care Referral Centers in India.Indian journal of pediatrics · 2026Article
- EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.American journal of hematology · 2026Article
- FPN1-8C>G Polymorphism as a potential genetic modifier of iron overload in transfusion-dependent β-Thalassemia major patients receiving HbF augmentation therapy.Pakistan journal of medical sciences · 2026Article
- Contemporary Management of Thalassemia: A Perspective on Current Standards and the Emergence of FDA-Approved Oral Therapy.Health science reports · 2026Article
- Green Tea Extract Attenuates Oxidative Stress and Prolongs Red Blood Cell Survival in Iron-Overloaded β-Thalassemic Mice.Antioxidants (Basel, Switzerland) · 2026Article
- Endocrinopathies and growth in a UK cohort of children with transfusion dependent thalassaemia.British journal of haematology · 2026Observational
- Article
- Thalassaemia.Nature reviews. Disease primers · 2026Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-thalassemia and particularly its transfusion-dependent form (TDT) is a demanding clinical condition, requiring life-long care and follow-up, ideally in specialized centers and by multidisciplinary teams of experts. Despite the significant progress in TDT diagnosis and treatment over the past decades that has dramatically improved patients' prognosis, its management remains challenging. On one hand, diagnostic and therapeutic advances are not equally applied to all patients across the world, particularly in several high-prevalence eastern regions. On the other, healthcare systems in low-prevalence western countries that have recently received large numbers of migrant thalassemia patients, were not ready to address patients' special needs. Thalassaemia International Federation (TIF), a global patient-driven umbrella federation with 232 member-associations in 62 countries, strives for equal access to quality care for all patients suffering from thalassemia or other hemoglobinopathies in every part of the world by promoting education, research, awareness, and advocacy. One of TIF's main actions is the development and dissemination of clinical practice guidelines for the management of these patients. In 2021, the fourth edition of TIF's guidelines for the management of TDT was published. The full text provides detailed information on the management of TDT patients and the clinical presentation, pathophysiology, diagnostic approach, and treatment of disease complications or other clinical entities that may occur in these patients, while also covering relevant psychosocial and organizational issues. The present document is a summary of the 2021 TIF guidelines for TDT that focuses mainly on clinical practice issues and recommendations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.